Accutar Announces Achievement of Milestone in Research Collaboration with Cytokinetics to Advance Targeted Protein Degraders for Muscle-Related Diseases

CRANBURY, N.J., Oct. 15, 2026 – Accutar Biotechnology today announced the achievement of a preclinical development milestone in its collaboration and licensing agreement with Cytokinetics, Incorporated to discover and develop novel targeted protein degraders to treat muscle-related diseases.

“We’re excited to have reached this first milestone in our research collaboration with Cytokinetics, a leading muscle-focused company whose deep disease biology expertise and commitment to innovation align well with our vision of transforming drug discovery through AI,” said Jie Fan, Ph.D., Chief Executive Officer of Accutar Biotechnology. “This collaboration represents a significant step in applying chimeric degraders beyond immunology and oncology.”

Under the research collaboration established in 2025, Accutar is leveraging its proprietary AI-driven discovery platform, which integrates advanced machine learning algorithms with high-resolution structural biology, to design and discover novel targeted protein degraders. Together the companies are sharing responsibility for preclinical development, with Cytokinetics contributing its expertise in muscle biology to guide candidate selection. Cytokinetics will be responsible for clinical development and commercialization of any selected candidates.

Upon achieving this preclinical development milestone, Accutar received an undisclosed milestone payment from Cytokinetics. Under the terms of the agreement, Accutar may be eligible to receive additional research, development and commercial milestone and royalty payments.

About Accutar Biotechnology

Accutar Biotechnology, Inc. is a clinical-stage biotechnology company dedicated to applying cutting-edge computational and experimental technologies for transformative drug discovery. The company’s proprietary AI platform integrates machine learning with structural biology to design and optimize novel therapeutics, including selective protein degraders, small molecules as well as small molecule antibody drug conjugates. Accutar’s pipeline includes multiple clinical-stage programs, demonstrating the platform’s ability to rapidly translate discoveries into potential therapies.

For more information, visit www.accutarbio.com